-
Vitamin C (CAS 50-81-7) Assay Guide
2026-09-15
A scenario-based guide to using Vitamin C (CAS 50-81-7), SKU B2064, in cell viability, proliferation, senescence, and cytotoxicity workflows. It connects dose selection, solution handling, orthogonal readouts, and supplier evaluation with product specifications and recent literature.
-
SmD2 Acetylation Links Splicing to PARP Sensitivity
2026-09-15
This study identifies SmD2 acetylation as a regulatory connection between core spliceosome stability, BRCA1/FANC cassette-exon usage, and DNA-damage responses in hepatocellular carcinoma. Its findings support combining HDAC-directed strategies with PARP inhibition to expose a potential vulnerability in BRCA-wild-type HCC models.
-
Rifampin Workflows for Transcription Research
2026-09-14
Rifampin provides a target-focused way to interrupt bacterial transcription and connect early RNA changes with downstream loss of growth or viability. This workflow guide covers formulation, time-course design, resistance studies, synthetic circuits, and troubleshooting while relating chemical transcription control to the light-regulated gene-switch principles described in a recent reference study.
-
Starvation, ER Calcium, and Cell Fate in Bombyx mori
2026-09-14
A 2026 study in Bombyx mori identifies an ER-Ca2+-calpain signaling axis that helps determine whether starvation-stressed fat-body cells remain in an autophagic state or progress to apoptosis. Its time-resolved design links energy depletion, altered SERCA and IP3R activity, calcium dysregulation, ATG5 cleavage, and caspase-3 activation, while 2-APB provides pharmacological evidence for an IP3R-dependent component.
-
Targeted mRNA Nanoparticles Repair the Stroke BBB
2026-09-13
The ACS Nano study developed M2 microglia-targeting lipid nanoparticles carrying IL-10 mRNA to reduce postischemic neuroinflammation, restore blood–brain barrier integrity, and improve neurological outcomes in mouse stroke models. Its central contribution is a delivery strategy that couples lesion targeting with an IL-10-driven feedback loop, while also highlighting important limits for translation to human mRNA therapeutics research.
-
Trelagliptin, RUNX2, and Osteoblast Differentiation
2026-09-12
The reference study identifies trelagliptin, a long-acting DPP-4 inhibitor, as a potential stimulator of osteoblastic differentiation in MC3T3-E1 cells through an AMPK-associated increase in RUNX2. Its findings support drug-repurposing research in osteoporosis, while the in vitro design requires validation in primary cells, animal models, and clinical studies.
-
3-Deazaneplanocin (DZNep) Assay Guide
2026-09-12
A scenario-based laboratory guide to using 3-Deazaneplanocin (DZNep), SKU A1905, in viability, proliferation, apoptosis, and cancer stem cell assays. It connects mechanism, formulation, protocol design, data interpretation, and practical product-selection criteria for more reproducible workflows.
-
Hexa His tag peptide: Clean His-Protein Elution
2026-09-11
Hexa His tag peptide enables soluble, antibody-competitive recovery of His-tagged proteins from magnetic-bead and conventional immunoprecipitation workflows. Its key advantage is cleaner eluate composition, helping reduce antibody heavy- and light-chain carryover during protein purification and protein interaction analysis.
-
Tacalcitol Sensitizes Colorectal Cancer to 5-FU
2026-09-11
The reference study identifies a VDR-dependent mechanism by which tacalcitol increases colorectal cancer cell sensitivity to 5-fluorouracil: induction of CDKN1A reduces thymidylate synthase at both transcript and protein levels. Its experiments also implicate VDR, CaSR, epithelial integrity, and survivin in treatment response, providing a mechanistic framework for vitamin D analog combination studies.
-
KCNE4-Dependent Modulation of Kv1.3 Pharmacology
2026-09-10
The reference study shows that the leukocyte auxiliary subunit KCNE4 changes the inhibition kinetics of Kv1.3 by the intracellular blocker Psora 4 without measurably changing blocker affinity. By comparing Psora 4 with the extracellular pore blocker margatoxin, the work links channel architecture and subunit stoichiometry to pharmacological interpretation in immune-cell models.
-
Methoxy-X04 Workflow for Amyloid Imaging
2026-09-10
Methoxy-X04 combines brain permeability with high-affinity aggregate labeling for plaque mapping, amyloid beta oligomer imaging, and cerebrovascular amyloid visualization. This practical guide connects probe handling and quantitative microscopy with the rTMS–microglia findings reported in a 2025 Alzheimer’s disease study.
-
Fucoidan and Chemotherapy-Induced Steatohepatitis
2026-09-09
A 2026 study identifies intestinal barrier failure, LPS translocation, and hepatic neutrophil extracellular traps as a connected pathway in irinotecan-induced steatohepatitis. Its findings position Fucoidan as a mechanistically testable intervention for preserving gut–liver homeostasis during chemotherapy, while leaving clinical efficacy and tumor-treatment interactions to future studies.
-
Panobinostat Targets MLL-Rearranged Leukemia
2026-09-09
This study shows that panobinostat produces substantial anti-leukaemic activity in xenograft models of MLL-rearranged acute lymphoblastic leukaemia. Its mechanistic contribution is the identification of RNF20/RNF40/WAC-dependent H2B ubiquitination as an epigenetic vulnerability that links HDAC inhibition to leukaemic cell death.
-
7-dehydro Cholesterol: Sterol Research Workflows
2026-09-08
Use 7-dehydro Cholesterol as a controlled DHCR7 substrate, a UVB-responsive precursor for vitamin D3 synthesis research, and an oxidation-sensitive sterol readout. This workflow-oriented guide connects chemical supplementation with lipid profiling, skin model research, and the dhcr7 knockout strategy reported in grass carp antiviral studies.
-
JAK Inhibitors and Endothelial Cardiovascular Effects
2026-09-08
This 2025 study compares how six JAK inhibitors modify inflammatory activation, coagulation-related gene expression, and apoptosis in human endothelial cells exposed to TNF plus IL-17A. Its central contribution is showing that reduced cytokine release does not necessarily eliminate adhesion-molecule induction, procoagulant signaling, or endothelial toxicity, emphasizing the need for compound-specific vascular profiling.